EUDA Health Holdings (NASDAQ:EUDA) has unveiled a nationwide stem cell extraction, cryostorage, and clinical delivery platform in China, marking a massive expansion of its footprint in the regional longevity and regenerative medicine sector.
MetLife Investment Management (MIM), the institutional asset management arm of MetLife (NYSE:MET), has finalized its acquisition of PineBridge Investments, significantly expanding its global footprint and total assets under management to $734.7 billion.
HUTCHMED (NASDAQ:HCM) announced on Tuesday that Chinese regulators have accepted its New Drug Application (NDA) for savolitinib and granted it priority review, clearing a path for the drug to become the first selective MET inhibitor approved for gastric cancer in the region.
Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) have begun an aggressive price-cutting campaign for their blockbuster obesity treatments in China, as the two pharmaceutical giants race to capture the world's largest patient population before local generic competition arrives.
ARS Pharmaceuticals (NASDAQ:SPRY) said China’s drug regulator has approved neffy 2 mg, an epinephrine nasal spray, for the emergency treatment of Type 1 allergic reactions in adults and children weighing at least 30 kilograms, marking the first epinephrine product authorized for community use in the country.
Tonix Pharmaceuticals (NASDAQ:TNXP) said it is advancing development plans for TNX-4800, a long-acting human monoclonal antibody designed for the prevention of seasonal Lyme disease, as the company prepares for regulatory discussions on potential late-stage clinical pathways.
GATX Corp. (NYSE:GATX) said it and Brookfield Infrastructure Partners L.P. (NYSE:BIP) have received all required regulatory approvals to complete their previously announced transaction to acquire Wells Fargo’s rail operating lease portfolio
Adlai Nortye (NASDAQ:ANL) said it has entered into an exclusive licensing agreement with ASK Pharm for the development and commercialization of its proprietary pan-RAS (ON) inhibitor, AN9025, in Greater China.
Praxis Precision Medicines (NASDAQ:PRAX) said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ulixacaltamide, a selective T-type calcium channel inhibitor being developed for the treatment of essential tremor, accelerating the regulatory path for the experimental therapy.
INOVIO (NASDAQ:INO) said the U.S. Food and Drug Administration has accepted for review its Biologics License Application for INO-3107, a DNA medicine being developed as a potential treatment for adults with recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus.
Verisk (NASDAQ:VRSK) has terminated its definitive agreement to acquire AccuLynx after the Federal Trade Commission failed to complete its review of the transaction by the Dec. 26, 2025 termination date specified in the merger agreement.
Mereo BioPharma (NASDAQ:MREO) said Phase 3 trials of setrusumab (UX143) in osteogenesis imperfecta failed to meet their primary endpoints, dealing a setback to the late-stage program as the company moves to cut spending and reassess priorities.
